Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 17,29 € (+13,01%). La mediana è 17,29 € (+13,01%).
| Acquista |
5 |
| Mantieni |
6 |
| Vendi |
1 |
Notizie Vai al feed delle notizie
Fortrea introduces Fortrea Intelligent Technology, an AI-powered suite to accelerate clinical trials
Fortrea has introduced Fortrea Intelligent Technology (FIT), a suite of people-centered, AI-powered solutions to automate workflows, optimize monitoring, and accelerate clinical trials. FIT builds on the Xcellerate platform and offers applications for biopharma, biotechnology, and medical device companies in full-service, functional-service, and SaaS models. The suite is organized into three pillars — lifecycle, foresight, and support — and provides role-based insights in near real time to improve predictability, quality, and productivity. » Altro su finanzen.net
Fortrea launches AI-powered technology suite Fortrea Intelligent Technology to support clinical trials
Fortrea introduced Fortrea Intelligent Technology (FIT), an AI-powered suite that includes extensions to the Xcellerate platform and new Lifecycle, Foresight and Companion modules. The tools automate workflows, integrate study data for role-specific insights and use AI/ML for pattern analysis and predictive signal generation; selected components will be offered as SaaS. The announcement comes as the stock trades below $10 and analysts project a return to profitability. » Altro su de.investing.com
Fortrea splits CMO and CPS roles: Oren Cohen remains CMO, Scott Dove becomes president of Clinical Pharmacology Services
Fortrea has reorganized its leadership team: Oren Cohen will focus exclusively on the role of chief medical officer with responsibility for medical strategy, scientific leadership, ethics and governance. Scott Dove will take over as president of Clinical Pharmacology Services, leading early clinical development solutions across Fortrea’s global network. Both are members of the executive committee and are expected to strengthen Fortrea’s client service and clinical pharmacology expertise. » Altro su finanzen.net
Dati finanziari dell'azienda
| (EUR) | giu 2026 | |
|---|---|---|
| Ricavi | 594,25 Mln | 1,39% |
| Utile lordo | 121,97 Mln | 26,22% |
| Utile netto | -11,57 Mln | 96,36% |
| EBITDA | 30,14 Mln | 110,83% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 1,51 Mld € |
Numero di azioni | 95,1 Mln |
Massimo/minimo a 52 settimane | 18,49 € - 7,18 € |
| Dividendi | No |
Beta | 1,97 |
Rapporto P/E | -19,75 |
Rapporto PEG | -0,10 |
Rapporto P/B | 3,30 |
Rapporto P/S | 0,65 |
Profilo aziendale
Fortrea Holdings Inc. bietet Lösungen für die klinische Entwicklung und den Zugang zu Patienten in der Biowissenschaftsbranche. Das Unternehmen bietet Management von klinischen Studien der Phasen I-IV, klinische Pharmakologie, differenzierte technologiegestützte Studienlösungen und Dienstleistungen nach der Zulassung. Das Unternehmen beliefert Pharma-, Biotechnologie- und Medizintechnikunternehmen. Fortrea Holdings Inc. hat seinen Sitz in Durham, North Carolina.
| Nome | FORTREA HOLDINGS DL-,001 Aktie |
| CEO | Anshul Thakral |
| Sede centrale | Durham,
nc Stati Uniti |
| Sito web | |
| Industria | Attrezzature e forniture sanitarie |
| Quotazione in borsa | 20/06/2023 |
| Dipendenti | 14.000 |
Deep Dive
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NASDAQ | FTRE |
Frankfurt | K67.F |
Düsseldorf | K67.DU |
München | K67.MU |
Scopri gli asset
Gli azionisti di FORTREA HOLDINGS DL-,001 Aktie investono anche nei seguenti asset
